Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überführung von ABX464 in die klinische Phase-3-Testung
DGAP-News: Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überführung von ABX464 in die klinische Phase-3-Testung
DGAP-News: Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überführung von ABX464 in die klinische Phase-3-Testung
DGAP-News: MicroVision Inc.: MicroVision to Participate in LiDAR Sensor Standards Consortium
DGAP-News: MicroVision Inc.: MicroVision to Participate in LiDAR Sensor Standards Consortium
DGAP-News: MicroVision Inc.: MicroVision to Participate in LiDAR Sensor Standards Consortium
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium
DGAP-News: Abivax' Phase-1/2-Studienergebnisse mit ABX196 zur Behandlung von Leberkrebs zeigen gute Sicherheit und vielversprechende Anzeichen klinischen Nutzens ...
DGAP-News: Abivax' Phase-1/2-Studienergebnisse mit ABX196 zur Behandlung von Leberkrebs zeigen gute Sicherheit und vielversprechende Anzeichen klinischen Nutzens ...
DGAP-News: Abivax' Phase-1/2-Studienergebnisse mit ABX196 zur Behandlung von Leberkrebs zeigen gute Sicherheit und vielversprechende Anzeichen klinischen Nutzens ...
DGAP-News: Eckert & Ziegler kooperiert mit University Health Network und CanProbe zur Anwendungserweiterung des Radiodiagnostikums PENTIXAFOR
DGAP-News: Eckert & Ziegler kooperiert mit University Health Network und CanProbe zur Anwendungserweiterung des Radiodiagnostikums PENTIXAFOR
DGAP-News: Eckert & Ziegler kooperiert mit University Health Network und CanProbe zur Anwendungserweiterung des Radiodiagnostikums PENTIXAFOR
DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
DGAP-News: Eckert & Ziegler kooperiert mit University Health Network und CanProbe zur Anwendungserweiterung des Radiodiagnostikums PENTIXAFOR
DGAP-News: Eckert & Ziegler kooperiert mit University Health Network und CanProbe zur Anwendungserweiterung des Radiodiagnostikums PENTIXAFOR
DGAP-News: Eckert & Ziegler kooperiert mit University Health Network und CanProbe zur Anwendungserweiterung des Radiodiagnostikums PENTIXAFOR
Is Merck Stock Undervalued After Its Colossal Earnings Growth?: https://www.marketbeat.com/logos/articles/med_20240906082957_is-merck-stock-undervalued-after-its-colossal-earn.jpg
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock: https://www.marketbeat.com/logos/articles/med_20240904162446_why-trevi-therapeutics-could-be-a-triple-bagger-bi.jpg
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock

Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics

Agilent Technologies Thrives From the Forever Chemicals Crackdown: https://www.marketbeat.com/logos/articles/med_20240903154945_agilent-technologies-thrives-from-the-forever-chem.jpg
Agilent Technologies Thrives From the Forever Chemicals Crackdown

Agilent Technologies Inc. (NYSE: A) is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software

AbbVie Stock Post Humira is Still an Attractive Stock to Hold: https://www.marketbeat.com/logos/articles/med_20240904081922_abbvie-stock-post-humira-is-still-an-attractive-st.jpg
AbbVie Stock Post Humira is Still an Attractive Stock to Hold

AbbVie (NYSE: ABBV) is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent

3 Stocks to Own if You Are Bearish on The Market: https://www.marketbeat.com/logos/articles/med_20240903134540_3-stocks-to-own-if-you-are-bearish-on-the-market.jpg
3 Stocks to Own if You Are Bearish on The Market

There are many reasons for the market to be bearish today, but the primary ones are the FOMC and the outlook for interest rates. The FOMC is set to cut rates this year, but the economic data isn’t

3 Stocks to Own if You Are Bearish on The Market: https://www.marketbeat.com/logos/articles/med_20240903134540_3-stocks-to-own-if-you-are-bearish-on-the-market.jpg
3 Stocks to Own if You Are Bearish on The Market

There are many reasons for the market to be bearish today, but the primary ones are the FOMC and the outlook for interest rates. The FOMC is set to cut rates this year, but the economic data isn’t

3 Bargain-Priced Growth Stocks for Fall 2024: https://www.marketbeat.com/logos/articles/med_20240903134414_3-bargain-priced-growth-stocks-for-fall-2024.jpg
3 Bargain-Priced Growth Stocks for Fall 2024

While market volatility may initially unsettle investors, it presents an opportunity to capitalize on discounted investment prospects. While the current bull market has favored some sectors, it

3 Bargain-Priced Growth Stocks for Fall 2024: https://www.marketbeat.com/logos/articles/med_20240903134414_3-bargain-priced-growth-stocks-for-fall-2024.jpg
3 Bargain-Priced Growth Stocks for Fall 2024

While market volatility may initially unsettle investors, it presents an opportunity to capitalize on discounted investment prospects. While the current bull market has favored some sectors, it

Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally: https://www.marketbeat.com/logos/articles/med_20240822125851_diabetes-and-neuro-products-ignite-medtronics-q1-e.jpg
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally

Shares of medical device manufacturer Medtronic PLC (NYSE: MDT) are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal